How many insider trades does FilingIQ track for INGN?

FilingIQ tracks 1,292 Form 4 insider transactions for INGN (Inogen Inc), covering filings from Nov 5, 2014 onwards. 55 of those were filed in the last 90 days.

Are INGN insiders net buyers or net sellers?

Across the full Form 4 history for INGN, 4 transactions (0%) were open-market purchases and 436 (34%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INGN in?

Inogen Inc (INGN) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $156.10M.

INGN insider trading

NasdaqGS Healthcare

Inogen Inc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,292

Last 90 days

Buys / sells

0% / 34%

Market cap

$156.10M

About Inogen Inc

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Company website: www.inogen.com

INGN insider activity at a glance

FilingIQ has scored 1,292 insider transactions for INGN since Nov 5, 2014. The most recent filing in our index is dated Apr 6, 2026.

Across the full history, 4 open-market purchases and 436 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INGN insider trades is 52.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for INGN?: FilingIQ tracks 1,292 Form 4 insider transactions for INGN (Inogen Inc), covering filings from Nov 5, 2014 onwards. 55 of those were filed in the last 90 days.
Are INGN insiders net buyers or net sellers?: Across the full Form 4 history for INGN, 4 transactions (0%) were open-market purchases and 436 (34%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INGN in?: Inogen Inc (INGN) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $156.10M.

Methodology & sources

Every INGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.